Personalized cancer vaccine with toripalimab for resected NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a personalized cancer vaccine, alone or with toripalimab (a drug that helps your immune system fight cancer), in people with non-small cell lung cancer (NSCLC) that was removed by surgery. It aims to see if the vaccine is safe and could help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer and are receiving or will receive treatment before or after surgery.
- You are in fairly good health (able to do daily activities) and expected to live at least 6 more months.
- Your organs (like liver, kidneys, bone marrow) are working well enough.
- You agree to use effective birth control if there is a chance of pregnancy, and you are not pregnant or breastfeeding.
- You have not had other cancers in the last 5 years (except for a few early or cured types).
- You do not have active infections, serious lung problems (like scarring or tuberculosis), or recent major heart or blood vessel issues.
- You are not allergic to the study vaccines or toripalimab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug called toripalimab. The vaccine is designed specifically for your tumor and may help your body's immune system fight cancer better after surgery or standard treatment.
This trial tests a personalized vaccine designed to train your immune system to fight any remaining cancer cells after surgery or during standard therapy. It is for people with solid tumors who are stable and have no signs of disease getting worse.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This trial tests whether giving a drug called Toripalimab after surgery can help prevent early-stage non-squamous non-small cell lung cancer from coming back. It is for people whose tumors have high-risk features and PD-L1 levels of at least 1%.
This study tests whether a drug called toripalimab, given after lung cancer surgery, can help keep the cancer from coming back in people with early-stage non-small cell lung cancer. It uses a blood test (ctDNA) to look for leftover cancer cells and decide who might benefit most.
This trial tests a personalized mRNA vaccine (made from your tumor's unique markers) combined with the immunotherapy drug adebrelimab for people with non-small cell lung cancer. It may help your immune system fight cancer cells that remain after standard treatment.
Hear when a new Non-Small Cell Lung Cancer NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.